RecruitingPhase 3NCT07335211
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Sponsor
Huons Co., Ltd.
Enrollment
206 participants
Start Date
Jan 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- Adults aged 19 years and older
- Participants diagnosed with POAG or OH
- Have fully explained and understood the study and have voluntarily given written informed consent.
Exclusion Criteria2
- Acute or chronic angle-closure glaucoma
- Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
Interventions
DRUGHUC3-637-R
Ophthalmic solution instilled directly into the eye (topical ocular administration)
DRUGHUC3-637
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07335211
Related Trials
Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract
NCT074620002 locations
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
NCT072176781 location
UBM Evaluation After Combined Deep Sclerectomy With Trabeculotomy in Primary Open Angle Glaucoma
NCT074544471 location
DSLT for Reducing Medication in Glaucoma
NCT073908901 location
Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
NCT073229652 locations